
Join to view full profile
747 52nd StreetOakland, CA 94609
Phone+1 510-428-3631
Fax+1 510-601-3916
Dr. Hastings is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCSF Benioff Children’s Hospital OaklandFellowship, Pediatric Hematology/Oncology, 1989 - 1992
UCSF Benioff Children’s Hospital OaklandResidency, Pediatrics, 1986 - 1989
University of California, Davis, School of MedicineClass of 1986
Certifications & Licensure
CA State Medical License 1987 - 2028
NV State Medical License 1992 - 2019
American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
- PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children Start of enrollment: 2012 Dec 13
- Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas Start of enrollment: 2014 Apr 29
Publications & Presentations
PubMed
- 2 citations2025 Consensus Clinical Management Guidelines for Niemann-Pick Disease Type C.Tarekegn Hiwot, Forbes D Porter, Tatiana Bremova-Ertl, Uma Ramaswami, Caroline Hastings
Journal of Inherited Metabolic Disease. 2026-05-01 - 1 citationsImplications of the choroid plexus in Niemann-Pick disease Type C neuropathogenesis.Raquel van Gool, Mariesa Cay, Boyu Ren, Kailey Brodeur, Emma Golden
Brain, Behavior, and Immunity. 2025-02-01 - 1 citationsThe Utility of Serum Alpha-fetoprotein for Monitoring for Relapse of Alpha-fetoprotein-Positive Hepatoblastoma.Monica Davini, Caroline Hastings, James Feusner
Journal of Pediatric Hematology/oncology. 2024-05-01
Press Mentions
Oxford Mom Helps Get First Drugs Approved for Treatment of a Rare Disease That Impacts Both of Her SonsJune 28th, 2025- Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)October 18th, 2022
- Cyclo Therapeutics Provides Business UpdateSeptember 29th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: